NKTX_OUT_1 [2025-03-27 11:24:44 -0400] 1967 Bytes | 583 tokens | Cum: 583 tkns (7.29% of 8k)
==========================================================================

Turbo, you got one job - predict the hottest stocks of the day -- before everyone else does! Ha! So today we're looking at Nkarta (NKTX) which is at 2.12 up from 1.37. So, I pulled together a bunch of data for you to look over real fast. It's still early, 11:24:42 AM on Thu Mar 27, 2025 -0400. So, what's the verdict? You're the expert!

Here's the first list of news for Nkarta:

C1 - Mar-26-25 04:01PM - Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights
C2 - Mar-20-25 09:35AM - Nkarta (NKTX) Loses -33.62% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
C3 - Mar-19-25 09:35AM - Nkarta (NKTX) Loses -32.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
C4 - Feb-25-25 08:01AM - Nkarta to Participate in March Investor Conferences
C5 - Dec-05-24 06:01AM - Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2
C6 - Nov-26-24 07:02AM - Nkarta to Participate in an Upcoming Investor Conference
C7 - Nov-22-24 06:50AM - Nkarta price target lowered to $16 from $20 at Mizuho
C8 - Nov-12-24 08:02AM - Nkarta to Participate in an Upcoming Investor Conference

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Nkarta (NKTX)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

NKTX_OUT_3 [2025-03-27 11:24:47 -0400] 1101 Bytes | 316 tokens | Cum: 901 tkns (11.26% of 8k)
==========================================================================

Showing C1 (chunk 1 of 12): C1:
**Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights**
Date: Mar-26-25 04:01PM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/03/26/3050104/0/en/Nkarta-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Corporate-Highlights.html

March 26, 2025 16:01 ET| Source:Nkarta, Inc.Nkarta, Inc.

SOUTH SAN FRANCISCO, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the fourth quarter and year ended December 31, 2024.

“As the validation of cellular therapy in autoimmune disease expands to include CAR NK cells, we remain confident that the potential safety and accessibility advantages of NKX019 will allow it to occupy an important place in the future t

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

NKTX_OUT_5 [2025-03-27 11:24:49 -0400] 853 Bytes | 266 tokens | Cum: 1169 tkns (14.61% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-27T05:27:44Z - TD Cowen Keeps Their Buy Rating on Nkarta (NKTX)...
A2 - 2025-03-26T21:04:44Z - Nkarta GAAP EPS of -$0.35 beats by $0.06 (NASDAQ:NKTX)...
A3 - 2025-03-26T20:01:00Z - Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights...
A4 - 2025-03-26T20:29:06Z - Nkarta (NKTX) to cut 34% staff...
A5 - 2025-03-26T20:13:13Z - Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

NKTX_OUT_7 [2025-03-27 11:24:54 -0400] 1098 Bytes | 308 tokens | Cum: 1479 tkns (18.49% of 8k)
==========================================================================

Showing A1 (chunk 1 of 2): A1:
**TD Cowen Keeps Their Buy Rating on Nkarta (NKTX)**Date: 2025-03-27Source: {'uri': 'markets.businessinsider.com', 'dataType': 'news', 'title': 'Markets Insider'}URL: https://markets.businessinsider.com/news/stocks/td-cowen-keeps-their-buy-rating-on-nkarta-nktx-1034518849Discover stocks' market position with detailed competitor analyses.

Werber covers the Healthcare sector, focusing on stocks such as Ascendis Pharma, Genmab, and Springworks Therapeutics. According to TipRanks, Werber has an average return of 7.4% and a 48.99% success rate on recommended stocks.

Nkarta has an analyst consensus of Moderate Buy, with a price target consensus of $7.00.

Based on Nkarta's latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $28.34 million. In comparison, last year the company had a GAAP net loss of $25.65 million

Based on the re

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

NKTX_OUT_9 [2025-03-27 11:24:55 -0400] 933 Bytes | 293 tokens | Cum: 1875 tkns (23.44% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-11-26T12:02:00Z - Nkarta to Participate in an Upcoming Investor Conference
B2 - 2024-09-03T20:01:00Z - Nkarta to Participate in Upcoming Investor Conference
B3 - 2024-08-14T16:37:31Z - Why Nkarta Stock Is Soaring Today
B4 - 2024-07-16T10:02:18Z - Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President - GlobeNewswire
B5 - 2024-06-27T10:00:00Z - Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications
B6 - 2024-06-13T20:01:00Z - Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

NKTX_OUT_11 [2025-03-27 11:25:01 -0400] 590 Bytes | 175 tokens | Cum: 2052 tkns (25.65% of 8k)
==========================================================================

Showing B3 (chunk 1 of 1): B3:
**Why Nkarta Stock Is Soaring Today**Date: Unknown DateSource: Unknown SourceURL: https://www.fool.com/investing/2024/08/14/why-nkarta-stock-is-soaring-today/?source=iedfolrf0000001Nkarta's stock surged 11.1% after Raymond James upgraded the stock to a strong buy, citing the company's strong cash position and the potential of its lead candidate NKX019 in treating autoimmune diseases.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

NKTX_OUT_13 [2025-03-27 11:25:02 -0400] 805 Bytes | 202 tokens | Cum: 2326 tkns (29.07% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-26 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and related notes appearing else...

S2 - 2025-03-26 8-K Item 2.02 Results of Oper and Fin Cond.

On March 26, 2025, Nkarta, Inc. (the Company) issued a press release announcing the Companys financial results for the fourth quarter and year ended December 31, 2024. A copy of the Companys press release is attached here...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

NKTX_OUT_15 [2025-03-27 11:25:04 -0400] 1098 Bytes | 236 tokens | Cum: 2564 tkns (32.05% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and related notes appearing elsewhere in this Annual Report on Form 10-K. This discussion contains forward-looking statements that reflect our plans, estimates and beliefs, and involve risks and uncertainties. Our actual results and the timing of certain events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those discussed in the section titled Risk Factors included under Part I, Item 1A and elsewhere in this Annual Report on Form 10-K. See Cautionary Note Regarding Forward-Looking Statements in this Annual Report on Form 10-K.

Overview

We are a clinical-stage

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

NKTX_OUT_17 [2025-03-27 11:25:05 -0400] 1098 Bytes | 248 tokens | Cum: 2814 tkns (35.17% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer ("NK") cell therapies. Our lead pipeline program is NKX019, a chimeric antigen receptor-natural killer ("CAR NK") product candidate targeting the CD19 antigen for the treatment of patients with autoimmune diseases. Our CAR NK platform enables an on-demand, off-the-shelf approach involving scaled manufacturing to broaden patient access. We have developed proprietary technologies that enable us to generate an abundant supply of NK cells, increase NK-cell recognition of target antigens, enhance NK-cell fitness and freeze, store, and thaw our engineered NK cells for off-the-shelf administration. NKX019 is allogeneic, which means it is produced using cells from a different person than the patient(s) being treated, and it is produced in quantity, then frozen and therefore available for t

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

NKTX_OUT_19 [2025-03-27 11:25:26 -0400] 5374 Bytes | 1622 tokens | Cum: 4438 tkns (55.47% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+--------------------+-----------------------+-------------------------+----------------------+
| Volume: 11,899,406 | Perf Month: 13.61% | Option/Short: Yes / Yes | Sales Y/Y TTM: - |
+--------------------+-----------------------+-------------------------+----------------------+
| Avg Volume: 1.04M | Perf Quarter: -18.20% | Short Float: 18.91% | ROE: -30.40% |
+--------------------+-----------------------+-------------------------+----------------------+
| Rel Volume: 39.30 | Index: RUT | Short Ratio: 9.04 | ROI: -21.71% |
+--------------------+-----------------------+-------------------------+----------------------+
| RSI (14): 60.53 | Market Cap: 144.31M | Short Interest: 9.40M | Sales Surprise: - |
+--------------------+-----------------------+-------------------------+----------------------+
| ATR (14): 0.17 | Shs Outstand: 70.57M | Beta: 0.97 | EPS Surprise: 13.56% |
+--------------------+-----------------------+-------------------------+----------------------+
| SMA20: 23.03% | Shs Float: 49.72M | Sales Q/Q: - | P/E: - |
+--------------------+-----------------------+-------------------------+----------------------+
| SMA50: 2.14% | Inst Own: 80.61% | Sales past 5Y: -25.00% | Earnings: Mar 26 AMC |
+--------------------+-----------------------+-------------------------+----------------------+
| SMA200: -46.42% | Insider Own: 29.54% | Employees: 150 | |
+--------------------+-----------------------+-------------------------+----------------------+
| Perf Week: 36.33% | Insider Trans: -0.23% | Debt/Eq: 0.20 | |
+--------------------+-----------------------+-------------------------+----------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

Inside Trans: Nkarta, Inc. (NKTX) by Hager Alicia J. (Chief Legal Officer) on 2025-01-15
- Common Stock: 9584 shares at $2.2 (D)

Inside Trans: Nkarta, Inc. (NKTX) by HASTINGS PAUL J (Chief Executive Officer) on 2025-01-15
- Common Stock: 17378 shares at $2.2 (D)

Inside Trans: Nkarta, Inc. (NKTX) by Brandenberger Ralph (Chief Technical Officer) on 2025-01-15
- Common Stock: 7447 shares at $2.2 (D)

Inside Trans: Nkarta, Inc. (NKTX) by Levin Alyssa (See Remarks) on 2025-01-15
- Common Stock: 5838 shares at $2.2 (D)

Inside Trans: Nkarta, Inc. (NKTX) by Shook David (See Remarks) on 2025-01-15
- Common Stock: 8638 shares at $2.2 (D)

Inside Trans: Nkarta, Inc. (NKTX) by Mahmood Nadir (President) on 2025-01-03
- Common Stock: 62000 shares at $0 (D)
- Stock Option (right to buy): 123500 shares at $0 (D)

Inside Trans: Nkarta, Inc. (NKTX) by Hager Alicia J. (Chief Legal Officer) on 2025-01-03
- Common Stock: 52500 shares at $0 (D)
- Stock Option (right to buy): 105000 shares at $0 (D)

Inside Trans: Nkarta, Inc. (NKTX) by Brandenberger Ralph (Chief Technical Officer) on 2025-01-03
- Common Stock: 52500 shares at $0 (D)
- Stock Option (right to buy): 105000 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -110609000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 2.135
Average Volume: 1673256.22
30-Day High: 2.135
30-Day Low: 1.37

[Detailed Financials: Q3 2024]
- Total Assets: $532,034,000.0
- Total Liabilities: $101,161,000.0
- Total Equity: $430,873,000.0
- Current Assets: $290,150,000.0
- Current Liabilities: $22,468,000.0

[Income Statement: Q3 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.39

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $-63,438,000.0

[Detailed Financials: Q2 2024]
- Total Assets: $554,086,000.0
- Total Liabilities: $100,902,000.0
- Total Equity: $453,184,000.0
- Current Assets: $331,799,000.0
- Current Liabilities: $20,861,000.0

[Income Statement: Q2 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.34

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $-129,887,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

NKTX_OUT_21 [2025-03-27 11:25:31 -0400] 676 Bytes | 167 tokens | Cum: 4909 tkns (61.36% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

NKTX_IN_23 [2025-03-27 11:25:32 -0400] 126 Bytes | 29 tokens | Cum: 5028 tkns (62.85% of 8k)
==========================================================================

====================================
[2025-03-27 08:25:32] # Analysis Completed
Elapsed Time: 49.72 seconds